Brokerages Set Mylan (MYL) PT at $44.99
Mylan (NASDAQ:MYL) has been given an average recommendation of “Buy” by the twenty-three ratings firms that are covering the company, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $45.49.
MYL has been the subject of a number of research reports. Zacks Investment Research lowered shares of Mylan from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. Cantor Fitzgerald set a $41.00 target price on shares of Mylan and gave the stock a “hold” rating in a report on Tuesday, December 26th. UBS Group set a $46.00 target price on shares of Mylan and gave the stock a “buy” rating in a report on Monday, December 4th. Susquehanna Bancshares reaffirmed a “positive” rating and set a $55.00 target price (up previously from $47.00) on shares of Mylan in a report on Thursday, January 25th. Finally, BidaskClub raised shares of Mylan from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 19th.
Shares of Mylan (NASDAQ:MYL) traded up $0.28 during midday trading on Wednesday, reaching $40.97. 7,024,265 shares of the company traded hands, compared to its average volume of 5,550,000. The stock has a market cap of $20,950.00, a price-to-earnings ratio of 31.52, a PEG ratio of 1.09 and a beta of 1.35. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.95 and a current ratio of 1.13. Mylan has a 12 month low of $29.39 and a 12 month high of $47.82.
In other news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.69% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Rehmann Capital Advisory Group acquired a new position in Mylan in the fourth quarter valued at about $236,000. Xact Kapitalforvaltning AB lifted its position in Mylan by 11.5% in the fourth quarter. Xact Kapitalforvaltning AB now owns 80,209 shares of the company’s stock valued at $3,394,000 after buying an additional 8,249 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Mylan by 23.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 8,283 shares of the company’s stock valued at $349,000 after buying an additional 1,596 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in Mylan by 9.9% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 180,616 shares of the company’s stock valued at $7,642,000 after buying an additional 16,260 shares during the last quarter. Finally, Paragon Capital Management LLC acquired a new position in Mylan in the fourth quarter valued at about $260,000. 76.86% of the stock is currently owned by hedge funds and other institutional investors.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.